MAP2K7 and cancer: Although monotherapy with MEK inhibitors has shown limited clinical efficacy in patients with KRAS-mutant tumors, in other types of RAS mutant cancer patients, MEK inhibitors alone have exhibited considerable antitumor activity [73,74,75,76,77,78].